Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Ertugliflozin And Metformin Hcl

Ertugliflozin and Metformin HCl: A Comprehensive Overview

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. Effective management of T2DM often requires a combination of lifestyle modifications and pharmacological interventions. One such combination is Ertugliflozin and Metformin Hydrochloride, marketed under the brand name Segluromet. This fixed-dose combination (FDC) therapy aims to provide enhanced glycemic control through complementary mechanisms of action.

Pharmacology

  • Ertugliflozin: A sodium-glucose co-transporter 2 (SGLT2) inhibitor, ertugliflozin works by blocking the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By inhibiting this transporter, ertugliflozin promotes the excretion of excess glucose through urine, thereby lowering blood glucose levels.

  • Metformin Hydrochloride: As a biguanide, metformin primarily acts by decreasing hepatic glucose production and enhancing insulin sensitivity in peripheral tissues. It also improves glucose uptake and utilization, contributing to reduced blood glucose levels.

When combined, these two agents offer a multifaceted approach to managing T2DM, addressing both insulin resistance and excess glucose production.

Clinical Indications

Segluromet is indicated for:

  • Adults with T2DM inadequately controlled on metformin alone: For patients whose blood glucose levels remain elevated despite optimal doses of metformin.

  • Adults already on both ertugliflozin and metformin: To simplify dosing regimens and improve adherence.

  • Adults with T2DM inadequately controlled on metformin and sitagliptin: Offering a combination therapy that includes a DPP-4 inhibitor.

By combining these agents, Segluromet provides a convenient once- or twice-daily oral option for patients, potentially improving adherence and overall treatment outcomes.

Efficacy

Clinical studies have demonstrated that Segluromet effectively reduces hemoglobin A1c (HbA1c) levels, a key marker of long-term blood glucose control. In patients inadequately controlled on metformin alone, the addition of ertugliflozin has shown to provide significant reductions in HbA1c levels. Moreover, improvements in fasting plasma glucose (FPG) and postprandial glucose levels have been observed. The combination therapy also offers benefits beyond glycemic control, including modest weight loss and reductions in systolic blood pressure, which are advantageous for many patients with T2DM who are at increased risk for cardiovascular events.

Safety Profile

While Segluromet is generally well-tolerated, potential side effects may include:

  • Gastrointestinal issues: Such as nausea, vomiting, and diarrhea, particularly during the initiation phase.

  • Genital mycotic infections: Due to increased glucose excretion in the urine, which can promote fungal growth.

  • Urinary tract infections (UTIs): A known risk with SGLT2 inhibitors.

  • Lactic acidosis: A rare but serious complication associated with metformin use, necessitating caution in patients with renal impairment.

Patients should be monitored regularly for renal function, and the medication should be discontinued in cases of acute kidney injury or significant renal decline.

Dosage and Administration

Segluromet is available in various strengths, typically combining 5 mg or 15 mg of ertugliflozin with 500 mg or 1000 mg of metformin. The specific dosage should be individualized based on the patient's current regimen, renal function, and treatment goals. It is recommended to take Segluromet with meals to minimize gastrointestinal side effects. Dosing adjustments may be necessary for patients with renal impairment, and the medication is contraindicated in those with severe renal dysfunction.

Conclusion

Ertugliflozin and Metformin Hydrochloride offer a promising combination therapy for the management of T2DM. By targeting multiple pathways involved in glucose regulation, this FDC provides enhanced glycemic control, potential weight loss, and cardiovascular benefits. As with all diabetic therapies, individualization of treatment is crucial, and patients should be regularly monitored to ensure optimal outcomes and minimize risks.

References

  1. Verywell Health. "Latest Medication Options for Diabetes." 

  2. Mayo Clinic. "Ertugliflozin and Metformin (Oral Route) Side Effects."

  3. PubMed. "Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes." 

  4. Mayo Clinic. "Ertugliflozin and Metformin (Oral Route) Description." 

  5. National Center for Biotechnology Information. "Product Information - Common Drug Review New Combination Product: Ertugliflozin/Metformin Fixed-Dose Combination (Segluromet)."